CERo Therapeutics Holdings, Inc.
CERO
$9.46
$0.232.49%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -21.06% | 6.00% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 143.70% | -52.40% | |||
| Operating Income | -143.70% | 52.40% | |||
| Income Before Tax | -859.92% | 115.89% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -859.92% | 115.89% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -859.92% | 115.89% | |||
| EBIT | -143.70% | 52.40% | |||
| EBITDA | -151.64% | 53.38% | |||
| EPS Basic | 6.41% | 80.02% | |||
| Normalized Basic EPS | 30.60% | 74.78% | |||
| EPS Diluted | 6.41% | 80.02% | |||
| Normalized Diluted EPS | 30.60% | 74.78% | |||
| Average Basic Shares Outstanding | 175.82% | 150.14% | |||
| Average Diluted Shares Outstanding | 175.82% | 150.14% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||